Key result
Cytokine adsorption reduces inflammation in post-cardiac arrest syndrome, but survival benefit remains unproven.
Why the study?
Post-cardiac arrest syndrome is driven by systemic inflammation and ischemia-reperfusion injury, and cytokine adsorption has been proposed to mitigate this response and improve outcomes.
Does cytokine adsorption improve inflammatory modulation, hemodynamic stability, and survival in patients with post-cardiac arrest syndrome?
Does cytokine adsorption improve inflammatory modulation, hemodynamic stability, and survival in patients with post-cardiac arrest syndrome?
Cytokine adsorption is a safe and feasible adjunctive therapy that reduces inflammatory markers in post-cardiac arrest syndrome, but its impact on survival and neurological recovery requires further investigation in large randomized trials.
Cytokine adsorption should not yet alter post-cardiac arrest care; leaves open whether IL-6 reductions improve survival or neurology, warranting RCTs.
BACKGROUND: Post-cardiac arrest syndrome (PCAS) is a critical condition arising from systemic inflammation and ischemia-reperfusion injury, often leading to poor outcomes despite advanced supportive therapies. Cytokine adsorption has been proposed as a therapeutic approach to mitigate the inflammatory response and improve survival and recovery in PCAS patients. MATERIALS AND METHODS: This narrative review aims to synthesize and critically evaluate recent literature (2013-2024) on the role of cytokine adsorption in PCAS management, focusing on inflammatory modulation, clinical outcomes, and safety. A comprehensive search of PubMed, Cochrane Library, Embase, Medline Complete, Scopus and Web of Science identified 17 studies investigating cytokine adsorption in PCAS. Inclusion criteria encompassed clinical trials, observational studies, and preclinical investigations. RESULTS: Cytokine adsorption reduces inflammatory markers, particularly interleukin-6 (IL-6), in patients with PCAS. While some studies report modest improvements in hemodynamic stability and reduced vasopressor requirements, survival benefits remain inconsistent across the literature. CONCLUSIONS: Cytokine adsorption appears to be a safe and feasible intervention in PCAS, with potential benefits in inflammatory modulation and hemodynamic support. However, its impact on long-term survival and neurological recovery remains unclear. Future large-scale randomized controlled trials are needed to establish definitive clinical guidelines for its use in PCAS management.
No takes yet. Share an insight, caveat, or question.
Raimondo et al. (2026) conducted a review in Post-cardiac arrest syndrome (PCAS). Cytokine adsorption vs. Standard care was evaluated on Inflammatory modulation, clinical outcomes, and safety. Cytokine adsorption in post-cardiac arrest syndrome reduces inflammatory markers like IL-6 and may improve hemodynamic stability, but its impact on survival and neurological recovery remains unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: